PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes (PhaseBio)
Diabetes News Service
PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes (PhaseBio)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales